Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28860347 | 1.00 | KDR (0.44) | KDRLNPEPMAPTTDP1POLB | |
| SCHEMBL17486360 | 0.93 | KDR (0.44) | KDRLNPEPMAPTTDP1POLB | |
| SCHEMBL28220875 | 0.93 | PYGL (0.45) | CDK2 | |
| SCHEMBL17449960 | 0.79 | ITGB1 (0.46) | KDRLNPEPCDK2 | |
| SCHEMBL17486396 | 0.76 | LNPEP (0.52) | LNPEPMAPTTDP1POLBLY96 | |
| SCHEMBL17486458 | 0.75 | LY96 (0.44) | KDRLNPEPMAPTTDP1POLB | |
| SCHEMBL17486370 | 0.74 | LY96 (0.47) | MAPTTDP1POLBNPSR1KDM4E | |
| SCHEMBL27616693 | 0.74 | CTSL (0.60) | LNPEPMAPTTDP1POLBLY96 | |
| SCHEMBL28217498 | 0.73 | LNPEP (0.58) | LNPEPMAPTTDP1POLBLY96 | |
| SCHEMBL28217499 | 0.73 | LNPEP (0.58) | LNPEPMAPTTDP1POLBLY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975023-B1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-30 | — | — | EP | disclosed |
| CN-105051008-B | Guanidinobenzoic acid ester compounds | 武田药品工业株式会社 | 2018-05-29 | — | — | CN | disclosed |
| US-9969709-B2 | Guanidinobenzoic acid ester compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-2975023-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | Astellas Pharma Inc. (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | SERPINB1, REN, SPINT2 | KDR 4766/4885LNPEP 206/4885MAPT 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.